Advertisement

Advertisement

News

FDA Grants Fast Track Designation to Novel Therapy for Platinum-Resistant Ovarian Cancer

Medical Literature

Are Early Immunotherapy Reponses Predictive of Survival in Advanced Melanoma?

Medical Literature

Nivolumab Plus Relatlimab vs Nivolumab Alone in Advanced Melanoma

News

RMAT Designation Granted by the FDA for Gemogenovatucel-T in Advanced Ovarian Cancer

Medical Literature

Melanoma Brain Metastases: Assessing Intracranial Response to Immunotherapy

Medical Literature

Immunologic Responses to Allogeneic Vaccine in Patients With Melanoma

Medical Literature

Do Ovarian Tumor Cells Sabotage Nearby Cells Using Long Noncoding RNA?

Ghassan K. Abou-Alfa, MD, on Clinical Implications of Using Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma

Rana R. McKay, MD, on the Treatment Landscape for Metastatic RCC

View More

Advertisement

JNCCN Spotlights

Elotuzumab

UPDATE Nivolumab and Ipilimumab in Renal Cell Carcinoma

View More

More

News

Immunologic Responses to Allogeneic Vaccine in Patients With Melanoma

Melanoma Brain Metastases: Assessing Intracranial Response to Immunotherapy

View More

Advertisement

Published

Medical Literature

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

View More

Ongoing

CE Activities

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Case Series: Defining the Role of Immunotherapy Across Melanoma Care

Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors

Minimizing the Impact of imAEs and Maximizing Efficacy of ICIs: AEs Affecting the Skin

View More

Available

Clinical Trials

A Study to Learn About the Effects of the Combination of Elranatamab

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

View More

Resources

For Your Patients

ONS Immunotherapy News

ONS Immunotherapy Community

Society for Immunotherapy of Cancer Patient Resources

CancerCare on Immunotherapy

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2025 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.